Table 3.

Changes in summed SUVmax and PSA in individual patients with mCRPC after 1 and 6 cycles of Docetaxel

Patient	% ∆ after the 1st cycle	% ∆ after the 6th cycle	% ∆ PSA after 1st cycle	% ∆ PSA after the 6th cycle
1	26.3	-	0.0	-
2	-28.6	-47.2	-51.7	-84.2
3	-11.9	-13.2	-20.7	-28.5
4	-20.6	-34.4	-6.1	-75.8
5	-6.2	-	100	-
6	-2.2	0.8	68.3	62.5
7	65.8	-	22.4	-

Δ= change.